- Advanced search
- Immuno Portal
- Malaria Portal
Synonyms: ALL-3 | AST-1306 | AST1306
Compound class: Synthetic organic
Comment: Allitinib (AST-1306) is an irreversible inhibitor of the wild-type epidermal growth factor receptor (EGFR) and ErbB2 (HER2) . It also inhibits the mutant EGFRT790M/L858R. Allitinib was designed by Allist Pharmaceuticals to overcome acquired resistance to EGFR inhibitor therapy. It is active in vitro and in vivo.
Allitinib is a 'pseudo' INN, that takes the form of an INN, but has not been submitted to the World Health Organisation for ratification.
Ligand Activity Visualisation Charts
These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.✖
|Compound class||Synthetic organic|
|ALL-3 | AST-1306 | AST1306|
|GtoPdb PubChem SID||363894206|
|Search Google for chemical match using the InChIKey||MVZGYPSXNDCANY-UHFFFAOYSA-N|
|Search Google for chemicals with the same backbone||MVZGYPSXNDCANY|
|UniChem Compound Search for chemical match using the InChIKey||MVZGYPSXNDCANY-UHFFFAOYSA-N|
|UniChem Connectivity Search for chemical match using the InChIKey||MVZGYPSXNDCANY-UHFFFAOYSA-N|